Leveraging digital to drive value for your cardiovascular therapies

With half a billion cardiovascular disease patients worldwide, it's no wonder the cardiovascular drug market is projected to hit $63.96 billion in 2026. Digital solutions are on the rise in this space, and cardiovascular is currently the fifth most active therapeutic area for SaMD.

In this white paper, we're diving into the challenges in bringing new digital solutions to market for use in treating cardiovascular disease, such as:

Complex conditions
Ongoing monitoring requirements
High financial and physical burden
Difficult lifestyle adjustments

We're also exploring opportunities to improve patient care and quality of life, while unlocking value for biopharma including:

New drug onboarding and dosing management
Comprehensive symptom tracking
HCP interfaces
Smart device integrations
Holistic care
Lifestyle modification coaching and rehabilitation

Download the white paper today to get the inside scoop on leveraging digital in the cardiovascular disease space, and to discover additional challenges and opportunities.